Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial-Reference-Cited by-同舟云学术

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Published:2019-07-15 Issue:4 Volume:121 Page:318-324
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Veitch Zachary W.,Cescon David W.,Denny Trisha,Yonemoto Lisa-Maria,Fletcher Graham,Brokx Richard,Sampson Peter,Li Sze-Wan,Pugh Trevor J.,Bruce Jeffrey,Bray Mark R.,Slamon Dennis J.,Mak Tak W.,Wainberg Zev A.,Bedard Philippe L.

Funder

Princess Margaret Cancer Foundation

California Institute for Regenerative Medicine

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0517-3.pdf

Reference18 articles.

1. Schoffski, P. Polo-like kinase (plk) inhibitors in preclinical and early clinical development in oncology. Oncologist 14, 559–570 (2009).

2. Archambault, V. & Glover, D. M. Polo-like kinases: conservation and divergence in their functions and regulation. Nat. Rev. Mol. Cell. Biol. 10, 265–275 (2009).

3. Lens, S. M. A., Voest, E. E. & Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10, 825–841 (2010).

4. Bettencourt-Dias, M. & Glover, D. M. Centrosome biogenesis and function: centrosomics brings new understanding. Nat. Rev. Mol. Cell. Biol. 8, 451–463 (2007).

5. Hu, Z., Fan, C., Oh, D. S., Marron, J. S., He, X., Qaqish, B. F. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QSAR, molecular docking, and dynamics-based computational discovery of potential PLK4 inhibitors for tumor therapy;Process Biochemistry;2024-11

2. CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer;Nature Communications;2024-06-29

3. Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma;Clinical Cancer Research;2024-06-07

4. CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer;2024-04-27

5. Design of novel PLK4 inhibitors as TRIM37-amplified breast cancer drugs using 3D-QSAR, molecular docking, and molecular dynamics simulation methods;Molecular Simulation;2024-04-04